The maker of Rice-A-Roni and Pasta Roni is aiming to help families simplify mealtime with its new Heat & Eat products.
As an easy-to-prepare meal option, the line features two selections — penne alfredo and rotini marinara — which microwave in 60 seconds, the Chicago-based company said.
“We know the most irreplaceable asset for families is time, which is why we keep innovating to help make meal prep less chaotic,” said Michelle McAlister, senior director of marketing at Quaker Foods North America. “With its familiar and dependable flavors similar to the other Heat & Eat varieties, Pasta Roni Heat & Eat will help make meal prep a breeze for busy families in search of delicious and convenient dinner options with less hassle.”
Consumers can find Pasta Roni Heat & Eat meal options at retailers nationwide for the suggested retail price of $2.39.
Ear care company Eosera is broadening its retail footprint.
The company recently announced that its products are now available at such retailers as Walgreens, Walmart, Albertsons and Kroger, as well as at its previously established locations including CVS Pharmacy, Rite Aid, Amazon and food stores.
This expansion brings Eosera’s products to 28,000 locations, the company said
“I am thrilled to see our products launch in major stores, such as Walgreens, Walmart, Albertsons and Kroger,” said Eosera co-founder and CEO Elyse Stoltz Dickerson.
“Our ultimate goal is to heighten the conversation around ear health, shed light on some of the most common ailments that can occur and allow people to avoid doctors’ visits through preventive care,” she said. “We’re confident that the increased presence of our products in 28,000 retailers nationwide will continue to educate consumers on the proper ways to take care of their ears at home.”
Products available include its flagship Earwax MD, Wax Blaster MD, Ear Pain MD and Ear Itch MD.
AAM: Build Back Better Act negotiations erode incentives for generics, biosimilars development
The Association for Accessible Medicines issued a statement of disapproval from president and CEO Dan Leonard on the Build Back Better Act’s negotiations framework.
“This flawed, untested scheme will reduce future savings through lower cost generic and biosimilar medicines for America’s patients and employers,” said Leonard. “The Build Back Better Act’s negotiations framework severely erodes the incentives for generic and biosimilar development. Generic and biosimilar manufacturers will be less likely to incur the costs and risks associated with developing new generic and biosimilar medicines in the future, which will diminish market-based competition against brand-name drugs and reduce the opportunity for additional savings.”
Leonard added, “Millions of America’s patients are desperate for meaningful solutions that address the high-cost of brand-name prescription drugs,” said Dan Leonard, president and CEO for the Association for Accessible Medicines. “Unfortunately, the Build Back Better Act merely undermines the only part of our healthcare system that year after year lowers prescription drug costs – competition from generic and biosimilar medicines.”
Mark your calendars. The National Association of Chain Drugs Stores announced today that registration is now open for its NACDS Annual Meeting.
NACDS invites you to join NACDS chair Brian Nightengale, president of Good Neighbor Pharmacy, from April 22 to 25, 2023 at The Breakers in Palm Beach, Fla., for the 2023 NACDS Annual Meeting.
"This exclusive event is the only industry gathering leading the way for influential business executives from drug, food and mass retailers, along with their supplier counterparts, to advance industry trends, strengthen relationships and explore new opportunities," NACDS said.
American Regent and Provepharm Life Solutions are offering ProvayBlue (methylene blue) injection in a 10 ml single-dose vial.
ProvayBlue is indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia.
The new vial presentation joins the ampule that American Regent and Provepharm Life Solutions have been marketing since 2016.
Provepharm has licensed exclusive rights to American Regent to market and distribute ProvayBlue in the United States.
“We are pleased that our continued partnership with Provepharm provides the opportunity to expand our line of ProvayBlue products to better meet the needs of providers and patients,” said Joann Gioia, vice president and chief commercial officer at American Regent.